Currency converter
24 Apr 2026 21:59
(0.03%)
Closing price, the previous day.
Opening price.
The highest price over the last trading day.
The lowest price over the last trading day
Price range high in the last week
Price range low in the last week
Az InstaSpot-csapat legendája!
Ha ezt a szót túlságosan bombasztikusnak gondolná, akkor hogyan nevezné az embert, aki 18 évesen első ázsiaiként megnyerte a junior sakkvilágbajnokságot, majd 19 évesen az első indiai nagymester lett? Ez csak a kezdete volt a rögös útnak, amely Visuvanátan Ánandot a világbajnokság felé vezette. Győzelmével beírta magát a történelemkönyvekbe, az InstaSpot pedig rendkívül büszke, hogy újabb legendával bővült partnerei listája.
A Borussia az egyik legtöbb címet elnyert német focicsapat, amely már többször bebizonyította rajongóinak: a versenyszellem és jó vezetés egyértelműen sikerhez vezet. Kereskedjen úgy, ahogy a profik játszák a játékot: magabiztosan és aktívan. Legyen Önnél a labda, lépjen be a legjobbak közé az InstaSpot-szel!
AbbVie Inc. is an American biopharmaceutical company. It was founded in 2013 after Abbott Laboratories split into two separate companies. In the same year, AbbVie Inc. was listed on the New York Stock Exchange as a separate company under the ABBV ticker.
The company’s mission is to develop and deliver innovative medicines that solve serious health issues. Since its foundation, the company has invested more than $50 billion in the research and development of world-class medicines.
Nowadays, it employs more than 50,000 people worldwide. Its production facilities and research centers are located in 20 countries.
In 2021, the company's total revenue amounted to $56.2 billion. AbbVie's GAAP net profit for the 6 months of 2022 totaled $5.42 billion, an increase of 25.4% compared to $4.32 billion in the previous year. Its revenue jumped by 4.3% to $28.12 billion against $26.97 billion a year earlier.
Currently, the company's shares are traded between $140-145, which is four times higher since its IPO 10 years ago. Over the past year, the stock price has fluctuated in the range of $106.86 -$175.91.
Its shares are growing slowly but surely without sharp price swings. Thus, the purchase of AbbVie Inc. stock can be deemed a good long-term investment.
AbbVie allocates 45-50% of available funds annually to pay dividends to its shareholders. The amount of dividends is quite decent. For this reason, the company is classified as a dividend aristocrat.